Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
|Articles|January 22, 2007
- Psychiatric Times Vol 24 No 1
- Volume 24
- Issue 1
Psychiatric Times Archives 2002
Psychiatric Times Archives 2002
Advertisement
December 2002
November 2002
October 2002
September 2002
August 2002
July 2002
June 2002
May 2002
April 2002
March 2002
February 2002
January 2002
Articles in this issue
almost 20 years ago
Antidepressants' Effects on Driving Abilityalmost 20 years ago
Green and Dyingalmost 20 years ago
Drugs for Kids: It's Time to Stop Medicating and Start Practicingalmost 20 years ago
Self-medication Prevalent in Patients With Anxiety Disordersalmost 20 years ago
Poetry of the Timesalmost 20 years ago
Congress Reduces Medicare Payment Cutalmost 20 years ago
Humorous Movies' Effects in Schizophreniaalmost 20 years ago
The Link Between Psychotic Disorders and Substance Usealmost 20 years ago
Intermittent Explosive Disorder: Common but Underappreciatedalmost 20 years ago
Accepting AcceptanceAdvertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Should Postpartum Psychosis Be Included in the DSM?
4
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
5